Saltar al contenido
Merck

LKB1 in endothelial cells is required for angiogenesis and TGFbeta-mediated vascular smooth muscle cell recruitment.

Development (Cambridge, England) (2008-06-10)
Anou Londesborough, Kari Vaahtomeri, Marianne Tiainen, Pekka Katajisto, Niklas Ekman, Tea Vallenius, Tomi P Mäkelä
RESUMEN

Inactivation of the tumor suppressor kinase Lkb1 in mice leads to vascular defects and midgestational lethality at embryonic day 9-11 (E9-E11). Here, we have used conditional targeting to investigate the defects underlying the Lkb1(-/-) phenotype. Endothelium-restricted deletion of Lkb1 led to embryonic death at E12.5 with a loss of vascular smooth muscle cells (vSMCs) and vascular disruption. Transforming growth factor beta (TGFbeta) pathway activity was reduced in Lkb1-deficient endothelial cells (ECs), and TGFbeta signaling from Lkb1(-/-) ECs to adjacent mesenchyme was defective, noted as reduced SMAD2 phosphorylation. The addition of TGFbeta to mutant yolk sac explants rescued the loss of vSMCs, as evidenced by smooth muscle alpha actin (SMA) expression. These results reveal an essential function for endothelial Lkb1 in TGFbeta-mediated vSMC recruitment during angiogenesis.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-actina, α-músculo liso monoclonal, clone 1A4, ascites fluid
Sigma-Aldrich
Anticuerpo anti-actina, αmúsculo liso- Cy3 monoclonal de ratón, clone 1A4, purified from hybridoma cell culture